Appointment of New Board Members
The Hong Kong Association of the Pharmaceutical Industry (HKAPI) has announced the election of two new members to its Board of Directors. Mr Neo Lam, from Baxter, and Mr Jonathan Chin, from Boehringer Ingelheim, have been elected to join the Board and will serve until the end of this term (2022-24).
Mr Neo Lam is the Business Units Director of Baxter Healthcare Ltd, bringing with him over 20 years of experience in the healthcare industry in Hong Kong & Macau, Asia Pacific market as well as Taiwan. He is passionate about policy sharping to drive healthcare solutions access, and improving patient outcomes through innovation and collaboration.
Mr Jonathan Chin is the General Manager, Hong Kong & Macau at Boehringer Ingelheim (HK) Ltd, with more than 20 years experience in the pharmaceutical industry across Asia Pacific, South America and India. He is committed to drive to achieve access to innovative Healthcare solutions for patients with high ethical standards in both Hong Kong and Macau.
We are delighted to welcome Mr Neo Lam and Mr Jonathan Chin to the HKAPI Board. Their extensive experience and deep knowledge of the healthcare industry will be invaluable as we work to drive positive change and support the growth of Hong Kong’s healthcare sector. As members of the HKAPI Board, Mr Lam and Mr Chin will work alongside other industry leaders to drive policy advocacy, promote innovation and collaboration, and support the development of a sustainable healthcare ecosystem in Hong Kong.
